Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barre and Miller Fisher syndrome

Journal of Neuroimmunology

Volumn 79, Issue 1, 1997, Pages 62-68

  Jacobs, B C ^a   Endtz, H Ph ^b   Van Der Meche F G A ^a   Hazenberg, M P ^a   De Klerk, M A ^a   Van Doorn, P A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Campylobacter jejuni; GMI; GQ1b; Guillain Barre syndrome; Lipopolysaccharides; Miller Fisher syndrome

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHOLERA TOXIN; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; SIALIDASE;

ANTIBODY TITER; ARTICLE; CAMPYLOBACTER JEJUNI; CLINICAL ARTICLE; CONTROLLED STUDY; ENTERITIS; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; PRIORITY JOURNAL; SUBCLAVIAN STEAL SYNDROME;

ANTIBODIES; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CAMPYLOBACTER JEJUNI; G(M1) GANGLIOSIDE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MILLER FISHER SYNDROME; POLYRADICULONEUROPATHY;

EID: 0030660329     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00110-0     Document Type: Article

References (32)

1. Ambrosino D.M., Delaney N.R., Shamberger R.C. Human polysaccharide-specific B cells are responsive to pokeweed mitogen and IL-6. J. Immunol. 144:1990;1221-1226.
2. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27(suppl):1990;S21-S24.
3. Aspinall G.O., McDonald A.G., Raju T.S., Pang H., Moran A.P., Penner J.L. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur. J. Biochem. 213:1993;1017-1027.
4. Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology. 43:1993;1911-1917.
5. Feinstein A., Richardson N., Taussig M.J. Immunoglobulin flexibility in complement activation. Immunol. Today. 7:1986;169-174.
6. Fujimoto S., Amako K. Guillain-Barré syndrome and Campylobacter jejuni infection. Lancet. 35:1990;1350.
7. Hammerström L., Smith C.I.E. IgG subclasses in bacterial infections. Monogr. Allerg. 19:1986;122-133.
8. Heidenreich F., Leifeld L., Jovin T. T cell-dependent activity of ganglioside GM1- specific B cells in Guillain-Barré syndrome and multifocal motor neuropathy in vitro. J. Neuroimmunol. 49:1994;97-108.
9. Jacobs B.C., Endtz H.Ph., Van der Meché F.G.A., Hazenberg M.P., Achtereekte H.A.M., Van Doorn P.A. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 37:1995;260-264.
10. Jacobs B.C., Van Doorn P.A., Schmitz P.I.M., Tio-Gillen A.P., Herbrink P., Visser L.H., Hooijkaas H., Van der Meché F.G.A. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 40:1996;181-187.
11. Jacobs B.C., Hazenberg M.P., Van Doorn P.A., Endtz H.Ph., Van der Meché F.G.A. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J. Infect. Dis. 175:1997;729-733.
12. Kaldor J., Tong M.Q., Dwyer B., Huang Z.H., Johnston N., Talman P., Horne M. Guillain-Barré syndrome and Campylobacter jejuni/coli. Pathology. 24:1992;125-126.
13. Klipstein F.A., Engert R.F. Properties of crude Campylobacter jejuni heat-labile enterotoxin. Infect. Immun. 45:1984;314-319.
14. Ogawa-Goto K., Funamoto N., Ohta Y., Abe T., Nagashima K. Myelin gangliosides of human peripheral nervous system: An enrichment of GM1 in the motor nerve myelin isolated from Cauda equina. J. Neurochem. 59:1992;1844-1849.
15. Ogino M., Nobile-Orazio E., Latov N. IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses. J. Neuroimmunol. 58:1995;77-80.
16. Oomes P.G., Jacobs B.C., Hazenberg M.P.H., Bänffer J.R.J., Van der Meché F.G.A. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry. Ann. Neurol. 38:1995;170-175.
17. Papadea C., Check I.J. Human immunoglobulin G and immunoglobulin G subclasses: Biochemical, genetic, and clinical aspects. Crit. Rev. Clin. Lab. Sci. 27:1989;27-58.
18. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. Campylobacter jejuni infection in Guillain-Barré syndrome. N. Engl. J. Med. 333:1995;1374-1379.
19. Rees J.H., Gregson N.A., Hughes R.A.C. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 38:1995;809-816.
20. Salloway S., Mermel L.A., Seamans M., Aspinall G.O., Nam Shin J.E., Kurjanczyk L.A., Penner J.L. Miller Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 64:1996;2945-2949.
21. Schwerer B., Neisser A., Polt R.J., Bernheimer H., Moran A.P. Antibody cross-reactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni sero-types associated with Guillain-Barré syndrome. J. Endotox. Res. 2:1995;395-403.
22. Suzuki S., Kawaguchi M., Mizuno K., Takama K., Yuki N. Immunological properties and ganglioside recognition by Campylobacter jejuni-enterotoxin and cholera toxin. FEMS Immunol. Med. Microbiol. 8:1994;207-212.
23. + currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37:1995;436-442.
24. Van der Meché F.G.A., Van Doorn P.A. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies. Ann. Neurol. 37(suppl.):1995;S14-S31.
25. Van de Winkel J.G.J., Capel P.J.A. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol. Today. 14:1993;215-221.
26. Walsh F.S., Cronin M., Koblar S., Doherty P., Winer J., Leon A., Hughes R.A.C. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J. Neuroimmunol. 34:1991;43-51.
27. Westphal O., Jann K. Bacterial lipopolysaccharides, extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5:1965;83-91.
28. Willison H.J., Kennedy P.G.E. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J. Neuroimmunol. 46:1993;105-112.
29. Willison H.J., Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 50:1994;159-165.
30. Yuki N., Taki T., Inagaki F., Takahashi M., Saito K., Handa S., Miyatake T. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178:1993;1771-1775.
31. Yuki N., Taki T., Takahashi M., Saito K., Yoshino H., Tai T., Handa S., Miyatake T. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 36:1994;791-793.
32. Yuki N., Ichihashi Y., Taki T. Subclass of IgG antibody to GM1 epitope-bearing lipo- polysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J. Neuroimmunol. 60:1995;161-164.